

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/026,949
Filing Date	December 27, 2001
First Named Inventor	Yusuf K. HAMIED et al.
Group Art Unit	1624
Examiner Name	Unassigned Coleman
Attorney Docket Number	33396-177202

RECEIVED

OCT 09 2003

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code ² (if known)			class	subclass
BC	A1	6,251,895		Larsen et al.	06-26-2001	514	220
	A2						
	A3						
	A4						
	A5						

TC 1700

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
BC	B1	EP	0831097		Lilly and Co.	03-25-1998		
BC	B2	EP	0733635		Lilly and Co.	09-25-1996		
BC	B3	WO	0018408		Lilly and Co.	04-06-2000		
	B4							
	B5							

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
** BC	C1	HOUBEN-WEYL, "Methoden der organischen Chemie, Band I/1, Allgemeine Laboratoriumspraxis I" 1958, GEORG THIEME VERLAG, STUTTGART XP002163768, pp. 381-382	
	C2		
	C3		
	C4		
	C5		

** Structures only

Examiner Signature	Brenda Coleman	Date Considered	Nov. 18, 2003
-----------------------	----------------	--------------------	---------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DC2948903

VENABLE
ATTORNEYS AT LAW

#4

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		Atty Docket: 33396-177202		Application No.: Unknown 10/026,949			
		Applicant: Y. HAMIED et al					
		Filing Date: December 27, 2001		Group: 1624			
U.S. PATENT DOCUMENTS							
Examiner Initial		U.S. Patent No.	Date	Name	Class	Sub-Class	Filing Date
	AA						
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
BC	AB ✓	R. Narendran et al. "Olanzapine Therapy in Treatment-Resistant Psychotic Mood Disorders: A Long-Term Follow-Up Study", <u>J Clin Psychiatry</u> . 62:7, July 2001, pp. 509-516.					
BC	AC ✓	J. Kando et al. "Olanzapine: A new Antipsychotic Agent with Efficacy in the Management of Schizophrenia", <u>The Annals of Pharmacotherapy</u> . November, 1997, Vol. 31, pp. 1325-1334.					
BC	AD ✓	P. Tran et al. "Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders", <u>Journal of Clinical Psychopharmacology</u> . Vol. 17, No. 5, pp. 407-418, 1997					
BC	AE ✓	F. Bymaster et al. "In Vitro and In Vivo Biochemistry of Olanzapine: A Novel, Atypical Antipsychotic Drug", <u>J Clin Psychiatry</u> . 1997; 58 (suppl 10), pp. 28-36.					
BC	AF ✓	C. Beasley et al. "Efficacy of Olanzapine: An Overview of Pivotal Clinical Trials", <u>J Clin Psychiatry</u> . 1997; 58 (suppl 10), pp. 7-12.					
BC	AG ✓	W. Glazer. "Olanzapine and the New Generation of Antipsychotic Agents: Patterns of Use", <u>J Clin Psychiatry</u> . 1997; 58 (suppl 10), pp. 18-21.					
BC	AH ✓	The Medical Letter, "On Drugs and Therapeutics". January 17, 1997, Vol. 38 (Issue 992), pp. 5-6.					
BC	AI ✓	C. Nemeroff. "Dosing the Antipsychotic Medication Olanzapine", <u>J Clin Psychiatry</u> . 1997; 58 (suppl 10), pp. 45-49.					
BC	AJ ✓	C. Guille et al. "A Naturalistic Comparison of Clozapine, Risperidone, and Olanzapine in the Treatment of Bipolar Disorder", <u>J Clin Psychiatry</u> . 61:9, September 2000, pp. 638-642.					
BC	AK ✓	W. Clark et al. "The Effects of Olanzapine in Reducing the Emergence of Psychosis Among Nursing Home Patients with Alzheimer's Disease", <u>J Clin Psychiatry</u> . 62:1, January 2001, pp. 34-39.					
BC	AL ✓	K. Littrell et al. "Switching Clozapine Responders to Olanzapine", <u>J Clin Psychiatry</u> . 61:12, December 2000, pp. 912-915.					
BC	AM ✓	J. Gomez et al. "Superior Efficacy of Olanzapine Over Haloperidol: Analysis of Patients with Schizophrenia From a Multicenter international Trial", <u>J Clin Psychiatry</u> . 2001:62, (suppl 2), pp. 6-10.					
BC	AN	M. Tohen et al. "Olanzapine Versus Placebo in the Treatment of Acute Mania", <u>Am J Psychiatry</u> . 156:5, May 1999, pp. 702-709.					
Examiner <i>Brenda Coleman</i>				Date Considered Nov. 18, 2003			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							


FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				Atty Docket 33396-153020		Page <u>3</u> of <u>5</u> Application No. 10/026,949 09/540,740	
							
				Filing Date March 31, 2000		Group <u>1624</u> Not Yet Assigned	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
BC	BA	4,115,574	9/19/78	Chakrabarti et al.	424	250	
BC	BB	5,457,101	10/10/95	Greenwood et al.	514	220	
BC	BC	5,627,178	5/6/97	Chakrabarti et al.	514	220	
BC	BD	5,631,250	5/20/97	Bunnell et al.	514	220	
BC	BE	5,637,584	6/10/97	Larsen	514	220	
BC	BF	5,703,232	12/30/97	Bunnell et al.	540	557	
BC	BG	5,817,655	10/6/98	Chakrabarti et al.	514	220	
BC	BH	5,817,656	10/6/98	Beasley, Jr. et al.	514	220	
BC	BI	5,817,657	10/6/98	Beasley, Jr. et al.	514	220	
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
BC	BJ	Drugs of the Future, <u>Olanzapine</u> , 1994, Vol. 19(2), pp. 114-117.					
BC	BK	Chakrabarti et al., <u>4-Piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as Potential Neuroleptics</u> , J. Med. Chem, 1980, Vol. 23, pp. 878-884.					
Examiner <u>Brenda Coleman</u>						Date Considered <u>Nov. 18, 2003</u> <u>March 27, 2004</u>	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

#4

Page 5 of 5

FORM PTO-1449	Atty Docket 33396-153020	Application No. 10/026,949 09/540,749
INFORMATION DISCLOSURE STATEMENT		
	Filing Date March 31, 2000	Group 1624 Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
BC	AA	5,919,485	7/6/99	Cochran et al.	424	480	 J1046 U.S. PTO 10/026949 12/27/01
BC	AB	5,736,541	4/7/98	Bunnell et al.	514	220	
BC	AC	5,229,382	7/20/93	Chakrabarti et al.	514	220	
BC	AD	5,605,897	2/25/97	Beasley, Jr. et al.	514	220	
BC	AE	4,115,568	9/19/78	Chakrabarti et al.	424	250	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Translation
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

BC	AL	Chakrabarti, et al., <u>10-Piperaziny-4H-thieno[3,2-b][1,5]- and -[3,4-b][1,5]benzodiazepines as Potential Neuroleptics</u> , J. Med. Chem. 1980, Vol. 23, 884-889.
BC	AM	Chakrabarti, et al., <u>Effects of Conformationally Restricted 4-Piperaziny-10H-thienobenzodiazepine Neuroleptics on Central Dopaminergic and Cholinergic Systems</u> , J. Med. Chem., 1982, Vol. 25, pp. 1133-1140.

Examiner Brenda Coleman Date Considered Nov. 18, 2003
March 22, 2004

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.